{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:05:59Z","timestamp":1791223559416,"version":"4.1.0"},"reference-count":142,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2004,10,1]],"date-time":"2004-10-01T00:00:00Z","timestamp":1096588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Microbiol Rev"],"published-print":{"date-parts":[[2004,10]]},"abstract":"<jats:sec><jats:title>SUMMARY<\/jats:title><jats:p>Hemolytic uremic syndrome (HUS) is a disease that can lead to acute renal failure and often to other serious sequelae, including death. The majority of cases are attributed to infections with<jats:italic>Escherichia coli<\/jats:italic>, serotype O157:H7 strains in particular, which cause bloody diarrhea and liberate one or two toxins known as Shiga toxins 1 and 2. These toxins are thought to directly be responsible for the manifestations of HUS. Currently, supportive nonspecific treatment is the only available option for the management of individuals presenting with HUS. The benefit of antimicrobial therapy remains uncertain because of several reports which claim that such intervention can in fact exacerbate the syndrome. There have been only a few specific therapies directed against neutralizing the activities of these toxins, but none so far has been shown to be effective. This article reviews the literature on the mechanism of action of these toxins and the clinical manifestations and current management and treatment of HUS. The major focus of the article, however, is the development and rationale for using neutralizing human antibodies to combat this toxin-induced disease. Several groups are currently pursuing this approach with either humanized, chimeric, or human antitoxin antibodies produced in transgenic mice. They are at different phases of development, ranging from preclinical evaluation to human clinical trials. The information available from preclinical studies indicates that neutralizing specific antibodies directed against the A subunit of the toxin can be highly protective. Such antibodies, even when administered well after exposure to bacterial infection and onset of diarrhea, can prevent the occurrence of systemic complications.<\/jats:p><\/jats:sec>","DOI":"10.1128\/cmr.17.4.926-941.2004","type":"journal-article","created":{"date-parts":[[2004,10,15]],"date-time":"2004-10-15T19:03:27Z","timestamp":1097867007000},"page":"926-941","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":104,"title":["Antibody Therapy in the Management of Shiga Toxin-Induced Hemolytic Uremic Syndrome"],"prefix":"10.1128","volume":"17","author":[{"given":"Saul","family":"Tzipori","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Tufts University School of Veterinary Medicine, North Grafton, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhineet","family":"Sheoran","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Tufts University School of Veterinary Medicine, North Grafton, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Akiyoshi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Tufts University School of Veterinary Medicine, North Grafton, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Donohue-Rolfe","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Tufts University School of Veterinary Medicine, North Grafton, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Trachtman","sequence":"additional","affiliation":[{"name":"North Shore-Long Island Jewish Research Institute, New Hyde Park, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-001-0783-0"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/319269"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.100.1.e12"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.36.7.2135-2137.1998"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01710530"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.36.6.1777-1780.1998"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0958-1669(97)80068-7","volume":"8","year":"1997","unstructured":"Bruggemann, M., and M. J. Taussig. 1997. Production of human antibody repertoires in transgenic mice. Curr. Opin. Biotechnol.8:455-458.","journal-title":"Curr. Opin. Biotechnol."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/jb.169.10.4759-4764.1987"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3201\/eid0504.990422","volume":"5","year":"1999","unstructured":"Chalmers, R. M., S. M. Parry, R. L. Salmon, R. M. Smith, G. A. Willshaw, and T. Cheasty. 1999. The surveillance of vero cytotoxin-producing Escherichia coli O157 in Wales, 1990 to 1998. Emerg. Infect. Dis.5:566-569.","journal-title":"Emerg. Infect. Dis."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011033"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/11717"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/9872","volume":"17","year":"1999","unstructured":"Chowdhury, P. S., and I. Pastan. 1999. Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat. Biotechnol.17:568-572.","journal-title":"Nat. Biotechnol."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2958.1996.427962.x"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1086\/315172"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2460\/javma.1997.210.06.789","volume":"210","year":"1997","unstructured":"Cowan, L. A., D. M. Hertzke, B. W. Fenwick, and C. B. Andreasen. 1997. Clinical and clinicopathologic abnormalities in greyhounds with cutaneous and renal glomerular vasculopathy: 18 cases (1992-1994). J. Am. Vet. Med. Assoc.210:789-793.","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-1759(00)00236-2"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.68.4.2356-2358.2000"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1086\/315421"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.1989.tb00273.x"},{"key":"e_1_3_2_21_2","first-page":"3645","volume":"67","year":"1999","unstructured":"Donohue-Rolfe, A., I. Kondova, J. Mukherjee, K. Chios, D. Hutto, and S. Tzipori. 1999. Antibody-based protection of gnotobiotic piglets infected withEscherichia coli O157:H7 against systemic complications associated with Shiga toxin 2. Infect. Immun. 67:3645-3648.","journal-title":"Antibody-based protection of gnotobiotic piglets infected with"},{"key":"e_1_3_2_22_2","unstructured":"Edwards A. C. A. R. Melton-Celsa K. Arbuthnott S. J. R. C. K. Schmitt H. C. Wong and A. O'Brien. 1998. Vero cell neutralization and mouse protective efficacy of humanized monoclonal antibodies against Escherichia coli toxins Stx1 and Stx2 p. 388-392. In J. B. Kaper and A. D. O'Brien (ed.) Escherichia coli O157:H7 and other Shiga toxin-producing E. coli strains. American Society for Microbiology Washington D.C."},{"key":"e_1_3_2_23_2","unstructured":"Essher Z. 1985. Monoclonal antibody strategy and techniques. Plenum Press New York N.Y."},{"key":"e_1_3_2_24_2","unstructured":"Fenwich R. W. and L. A. Cowan. 1998. Canine model of hemolytic uremic syndrome. In Escherichia coli O157:H7 and other Shiga toxin-producing E. coli strains p. 268-277. In J. B. Kaper and A. D. O'Brien (ed.) Escherichia coli O157:H7 and other Shiga toxin-producing E. coli strains. American Society for Microbiology Washington D.C."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0796-845"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.51.3.953-956.1986"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1086\/338115"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1006\/mpat.1999.0279"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1348-0421.1990.tb01019.x","volume":"34","year":"1990","unstructured":"Furutani, M., K. Ito, Y. Oku, Y. Takeda, and K. Igarashi. 1990. Demonstration of RNA N-glycosidase activity of a verotoxin (VT2 variant) produced by Escherichia coli 091:H21 from patient with the hemolytic uremic syndrome. Microbiol. Immunol.34:387-392.","journal-title":"Microbiol. Immunol."},{"key":"e_1_3_2_30_2","first-page":"117","volume":"9","year":"1994","unstructured":"Gallo, G., and C. Gianantonio. 1994. Extrarenal involvement in diarrhea-associated haemolytic-uremic syndrome. Pediatr. Nephrol.9:117-119.","journal-title":"Pediatr. Nephrol."},{"key":"e_1_3_2_31_2","first-page":"306","volume":"53","year":"1989","unstructured":"Gannon, V. P., C. L. Gyles, and B. P. Wilcock. 1989. Effects of Escherichia coli Shiga-like toxins (verotoxins) in pigs. Can. J. Vet. Res.53:306-312.","journal-title":"Can. J. Vet. Res."},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1099\/00221287-136-6-1125"},{"key":"e_1_3_2_33_2","first-page":"1682","volume":"186","year":"2003","unstructured":"Garcia, A., R. P. Marini, Y. Feng, A. Vitsky, K. A. Knox, N. S. Taylor, D. B. Schauer, and J. G. Fox. 2003. A naturally occurring rabbit model of enterohemorrhagic Escherichia coli-induced disease. J. Infect. Dis.186:1682-1686.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_34_2","first-page":"905","volume":"85","year":"1955","unstructured":"Gasser, C., C. Gautier, R. Steck, et al. 1955. Hamolytisch-uramische syndrome: bilaterle niernindennekrosen bei akuten erworbenen hamolytischen anamkien. Schweiz. Med. Weochenschr.85:905-909.","journal-title":"Schweiz. Med. Weochenschr."},{"key":"e_1_3_2_35_2","first-page":"493","volume":"15","year":"2002","unstructured":"Gerber, A., H. Karch, F. Allerberger, H. M. Verweyen, and L. B. Zimmerhackl. 2002. Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study. J. Infect. Dis.15;186:493-500.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2003.02057.x"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.epirev.a036079"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1309\/UMW9-D06Q-M94Q-JGH2"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9120(98)00041-1"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1993.tb12721.x"},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1749-6632.1995.tb55879.x","volume":"764","year":"1995","unstructured":"Harding, F. A., and N. Lonberg. 1995. Class switching in human immunoglobulin transgenic mice. Ann. N. Y. Acad. Sci.764:536-546.","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)67839-7"},{"key":"e_1_3_2_43_2","first-page":"211","volume":"51","year":"1988","unstructured":"Head, S. C., M. Petric, S. Richardson, M. Roscoe, and M. A. Karmali. 1988. Purification and characterization of verocytotoxin 2. FEMS Microbiol. Lett.51:211-216.","journal-title":"Purification and characterization of verocytotoxin 2. FEMS Microbiol. Lett."},{"key":"e_1_3_2_44_2","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1177\/030098589503200501","volume":"32","year":"1995","unstructured":"Hertzke, D. M., L. A. Cowan, P. Schoning, and B. W. Fenwick. 1995. Glomerular ultrastructural lesions of idiopathic cutaneous and renal glomerular vasculopathy of greyhounds. Vet. Pathol.32:451-459.","journal-title":"Vet. Pathol."},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199908000-00011"},{"key":"e_1_3_2_46_2","first-page":"357","volume":"52","year":"1999","unstructured":"Ikeda, K., O. Ida, K. Kimoto, T. Takatorige, N. Nakanishi, and K. Tatara. 1999. Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection. Clin. Nephrol.52:357-362.","journal-title":"Clin. Nephrol."},{"key":"e_1_3_2_47_2","first-page":"11","volume":"33","year":"1990","unstructured":"Islam, M. S., and W. H. Stimson. 1990. Production and characterization of monoclonal antibodies with therapeutic potential against Shiga toxin. J. Clin. Lab. Immunol.33:11-16.","journal-title":"J. Clin. Lab. Immunol."},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/0882-4010(90)90007-D"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.163.6.1391"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6968.1987.tb02252.x"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V961126"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.11.2755.2755"},{"key":"e_1_3_2_53_2","doi-asserted-by":"crossref","unstructured":"Karmali M. B. Steele M. Petric and C. Lim. 1983. Sporadic cases of haemolytic uremic syndrome associated with faecal cytotoxin and cytotoxin-producing E. coli in stools. Lancet i :619-620.","DOI":"10.1016\/S0140-6736(83)91795-6"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00868714"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.5.7.1750-1759.1985"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.63.3.1138-1141.1995"},{"key":"e_1_3_2_57_2","first-page":"161","volume":"21","year":"2002","unstructured":"Kimura, T., M. S. Co, M. Vasquez, S. Wei, H. Xu, S. Tani, Y. Sakai, T. Kawamura, Y. Matsumoto, H. Nakao, and T. Takeda. 2002. Development of humanized monoclonal antibody TMA-15 which neutralizes Shiga toxin 2. Hybrid Hybridomics21:161-168.","journal-title":"Development of humanized monoclonal antibody TMA-15 which neutralizes Shiga toxin 2. Hybrid Hybridomics"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1038\/35001095"},{"key":"e_1_3_2_59_2","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1136\/adc.65.7.722","volume":"65","year":"1990","unstructured":"Kleanthous, H., H. R. Smith, S. M. Scotland, R. J. Gross, B. Rowe, C. M. Taylor, and D. V. Milford. 1990. Haemolytic uraemic syndromes in the British Isles, 1985-1988: association with verocytotoxin producing Escherichia coli. 2. Microbiological aspects. Arch. Dis. Child.65:722-727.","journal-title":"2. Microbiological aspects. Arch. Dis. Child."},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/0966-842X(96)10017-2"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1159\/000187761"},{"key":"e_1_3_2_62_2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3109\/08830189509061738","volume":"13","year":"1995","unstructured":"Lonberg, N., and D. Huszar. 1995. Human antibodies from transgenic mice. Int. Rev. Immunol.13:65-93.","journal-title":"Int. Rev. Immunol."},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1038\/368856a0"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/172.5.1397"},{"key":"e_1_3_2_65_2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1203\/00006450-200208000-00026","volume":"52","year":"2002","unstructured":"Ludwig, K., E. Grabhorn, M. Bitzan, C. Bobrowski, M. J. Kemper, I. Sobottka, R. Laufs, H. Karch, and D. E. Muller-Wiefel. 2002. Saliva IgM and IgA are a sensitive indicator of the humoral immune response to Escherichia coli O157 lipopolysaccharide in children with enteropathic hemolytic uremic syndrome. Pediatr. Res.52:307-313.","journal-title":"Pediatr. Res."},{"key":"e_1_3_2_66_2","unstructured":"Mackenzie A. M. R. P. Rowe and P. McLaine. 2000. Stx1 and Stx2 among STEC-producing strains isolated from sporadic cases of HUS in Canada (personal communication)."},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1177\/030098589102800109"},{"key":"e_1_3_2_68_2","first-page":"235","volume":"30","year":"1999","unstructured":"Mainil, J. 1999. Shiga\/verocytotoxins and Shiga\/verotoxigenic Escherichia coli in animals. Vet. Res.30:235-257.","journal-title":"Vet. Res."},{"key":"e_1_3_2_69_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0022-1759(95)00018-6","volume":"183","year":"1995","unstructured":"Malmborg, A. C., and C. A. Borrebaeck. 1995. BIAcore as a tool in antibody engineering. J. Immunol. Methods183:7-13.","journal-title":"J. Immunol. Methods"},{"key":"e_1_3_2_70_2","first-page":"779","volume":"10","year":"1992","unstructured":"Marks, J. D., A. D. Griffiths, M. Malmqvist, T. P. Clackson, J. M. Bye, and G. Winter. 1992. By-passing immunization building high affinity human antibodies by chain shuffling. Biotechnology10:779-783.","journal-title":"Biotechnology"},{"key":"e_1_3_2_71_2","first-page":"281","volume":"44","year":"1987","unstructured":"Marques, L. R. M., J. S. M. Peiris, S. J. Cryz, and A. D. O'Brien. 1987. Escherichia coli strains isolated from pigs with edema disease produce a variant of Shiga-like toxin II. FEMS Microbiol. Lett.44:281-283.","journal-title":"FEMS Microbiol. Lett."},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1086\/317930"},{"key":"e_1_3_2_73_2","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1146\/annurev.bioeng.2.1.339","volume":"2","year":"2000","unstructured":"Maynard, J., and G. Georgiou. 2000. Antibody engineering. Annu. Rev. Biomed. Eng.2:339-376.","journal-title":"Antibody engineering. Annu. Rev. Biomed. Eng."},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0505.990502"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.7883\/yoken1952.51.Supplement1_S108"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0934-8840(11)80004-6"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.65.7.716"},{"key":"e_1_3_2_78_2","unstructured":"Moxley R. A. and D. H. Francis. 1998. Overview of animal models p. 249-260. In J. B. Kaper and A. D. O'Brien (ed.) Escherichia coli O157:H7 and other Shiga toxin-producing E. coli strains. American Society for Microbiology Washington D.C."},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.64.2.495-502.1996"},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.70.2.612-619.2002"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.70.10.5896-5899.2002"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M106015200"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2958.1998.00890.x"},{"key":"e_1_3_2_84_2","doi-asserted-by":"crossref","first-page":"6898","DOI":"10.4049\/jimmunol.163.12.6898","volume":"163","year":"1999","unstructured":"Nicholson, I. C., X. Zou, A. V. Popov, G. P. Cook, E. M. Corps, S. Humphries, C. Ayling, B. Goyenechea, J. Xian, M. J. Taussig, M. S. Neuberger, and M. Bruggemann. 1999. Antibody repertoires of four- and five-feature translocus mice carrying human immunoglobulin heavy chain and kappa and lambda light chain yeast artificial chromosomes. J. Immunol.163:6898-6906.","journal-title":"J. Immunol."},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.112058999"},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.172229899"},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.6387911"},{"key":"e_1_3_2_88_2","first-page":"65","volume":"180","year":"1992","unstructured":"O'Brien, A. D., V. L. Tesh, A. Donohue-Rolfe, M. P. Jackson, S. Olsnes, K. Sandvig, A. A. Lindberg, and G. T. Keusch. 1992. Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. Curr. Top. Microbiol. Immunol.180:65-94.","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"e_1_3_2_89_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.56.9.2373-2378.1988"},{"key":"e_1_3_2_90_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/160.6.994"},{"key":"e_1_3_2_91_2","doi-asserted-by":"publisher","DOI":"10.1099\/00222615-30-3-219"},{"key":"e_1_3_2_92_2","first-page":"64","volume":"9","year":"1991","unstructured":"Page, M. J., and M. A. Sydenham. 1991. High level expression of the humanized monoclonal antibody Campath-1H in Chinese hamster ovary cells. Biotechnology (N.Y.)9:64-68.","journal-title":"Biotechnology (N.Y.)"},{"key":"e_1_3_2_93_2","doi-asserted-by":"publisher","DOI":"10.1038\/73111"},{"key":"e_1_3_2_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/0882-4010(92)90023-H"},{"key":"e_1_3_2_95_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-1119(93)90700-D"},{"key":"e_1_3_2_96_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.11.3.450"},{"key":"e_1_3_2_97_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)81600-2"},{"key":"e_1_3_2_98_2","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/bjc.1994.459","volume":"70","year":"1994","unstructured":"Pedley, R. B., J. A. Boden, R. Boden, R. H. J. Begent, A. Turner, A. M. R. Haines, and D. J. King. 1994. The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody. Br. J. Cancer70:1126-1130.","journal-title":"Br. J. Cancer"},{"key":"e_1_3_2_99_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.26.10.2127-2131.1988"},{"key":"e_1_3_2_100_2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s004670050413","volume":"12","year":"1998","unstructured":"Perez, N., F. Spizziri, R. Rahman, A. Suarez, C. Larrubia, and P. Lasarte. 1998. Steroids in hemolytic uremic syndrome. Pediatr. Nephrol.12:101-104.","journal-title":"Pediatr. Nephrol."},{"key":"e_1_3_2_101_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.36.11.3317-3322.1998"},{"key":"e_1_3_2_102_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)81209-0"},{"key":"e_1_3_2_103_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-0734.2001.00044.x"},{"key":"e_1_3_2_104_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.5.1932-1937.2001"},{"key":"e_1_3_2_105_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004670100660"},{"key":"e_1_3_2_106_2","first-page":"110","volume":"4","year":"2002","unstructured":"Reichert, J. M. 2002. Therapeutic monoclonal antibodies: trends in development and approval in the U.S. Curr. Opin. Mol. Ther.4:110-118.","journal-title":"U.S. Curr. Opin. Mol. Ther."},{"key":"e_1_3_2_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)68906-4"},{"key":"e_1_3_2_108_2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/BF00867478","volume":"5","year":"1991","unstructured":"Robson, W. L. M., G. H. Fick, T. Jadavji, and A. K. Leung. 1991. The use of intravenous gammaglobulin in the treatment of atypical hemolytic uremic syndrome. Pediatr. Nephrol.5:289-292.","journal-title":"Pediatr. Nephrol."},{"key":"e_1_3_2_109_2","doi-asserted-by":"publisher","DOI":"10.1099\/00222615-40-5-338"},{"key":"e_1_3_2_110_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.8.996"},{"key":"e_1_3_2_111_2","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.66.3.1205-1208.2000"},{"key":"e_1_3_2_112_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.59.3.1065-1073.1991"},{"key":"e_1_3_2_113_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268800066462"},{"key":"e_1_3_2_114_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.71.6.3125-3130.2003"},{"key":"e_1_3_2_115_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi980946"},{"key":"e_1_3_2_116_2","doi-asserted-by":"publisher","DOI":"10.1159\/000046288"},{"key":"e_1_3_2_117_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(94)70001-X"},{"key":"e_1_3_2_118_2","doi-asserted-by":"publisher","DOI":"10.1086\/515258"},{"key":"e_1_3_2_119_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.50.3.695-700.1985"},{"key":"e_1_3_2_120_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8553(05)70208-9"},{"key":"e_1_3_2_121_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/20.1.1"},{"key":"e_1_3_2_122_2","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1093\/nar\/20.23.6287","volume":"20","year":"1992","unstructured":"Taylor, L. D., C. E. Carmack, S. R. Schramm, R. Mashayekh, K. M. Higgins, C. C. Kuo, C. Woodhouse, R. M. Kay, and N. Lonberg. 1992. A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins. Nucleic Acids Res.20:6287-6295.","journal-title":"Nucleic Acids Res."},{"key":"e_1_3_2_123_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V124800"},{"key":"e_1_3_2_124_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.61.8.3392-3402.1993"},{"key":"e_1_3_2_125_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02111832"},{"key":"e_1_3_2_126_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008480-199904000-00011"},{"key":"e_1_3_2_127_2","first-page":"1337","volume":"10","year":"2003","unstructured":"Trachtman, H., A. Cnaan, E. Christen, K. Gibbs, S. Zhao, D. W. Acheson, R Weiss, F. J. Kaskel, A. Spitzer, and G. H. Hirschman. 2003. Investigators of the HUS-SYNSORB Pk Multicenter Clinical Trial. Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. JAMA10:1337-1344.","journal-title":"JAMA"},{"key":"e_1_3_2_128_2","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1073\/pnas.90.8.3720","volume":"90","year":"1993","unstructured":"Tuaillon, N., L. D. Taylor, N. Lonberg, P. W. Tucker, and J. D. Capra. 1993. Human immunoglobulin heavy-chain minilocus recombination in transgenic mice: gene-segment use in mu and gamma transcripts. Proc. Natl. Acad. Sci. USA90:3720-3724.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"e_1_3_2_129_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/154.4.712"},{"key":"e_1_3_2_130_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.63.9.3621-3627.1995"},{"key":"e_1_3_2_131_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.41.10.1099"},{"key":"e_1_3_2_132_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.55.12.3117-3125.1987"},{"key":"e_1_3_2_133_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.57.4.1142-1150.1989"},{"key":"e_1_3_2_134_2","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-199806000-00008"},{"key":"e_1_3_2_135_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-1759(98)00077-5"},{"key":"e_1_3_2_136_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.58.8.2438-2445.1990"},{"key":"e_1_3_2_137_2","first-page":"185A","volume":"12","year":"2001","unstructured":"Wang, H., E. Christen, K. J. Tracey, and H. Trachtman. 2001. HMG-1 excretion is increased in children with diarrheal-associated hemolytic uremic syndrome. J. Am. Soc. Nephrol.12:185A (abstract).","journal-title":"J. Am. Soc. Nephrol."},{"key":"e_1_3_2_138_2","doi-asserted-by":"publisher","DOI":"10.1128\/jb.170.9.4223-4230.1988"},{"key":"e_1_3_2_139_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200006293422601"},{"key":"e_1_3_2_140_2","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.4049\/jimmunol.145.9.3011","volume":"145","year":"1990","unstructured":"Wood, C. R., A. J. Dorner, G. E. Morris, E. M. Alderman, D. Wilson, R. M. O'Hara, Jr., and R. J. Kaufman. 1990. High level synthesis of immunoglobulins in Chinese hamster ovary cells. J. Immunol.145:3011-3016.","journal-title":"J. Immunol."},{"key":"e_1_3_2_141_2","doi-asserted-by":"publisher","DOI":"10.1086\/338633"},{"key":"e_1_3_2_142_2","doi-asserted-by":"publisher","DOI":"10.1086\/323082"},{"key":"e_1_3_2_143_2","doi-asserted-by":"publisher","DOI":"10.1086\/315239"}],"container-title":["Clinical Microbiology Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CMR.17.4.926-941.2004","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CMR.17.4.926-941.2004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T01:12:44Z","timestamp":1734570764000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CMR.17.4.926-941.2004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10]]},"references-count":142,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,10]]}},"alternative-id":["10.1128\/CMR.17.4.926-941.2004"],"URL":"https:\/\/doi.org\/10.1128\/cmr.17.4.926-941.2004","relation":{},"ISSN":["0893-8512","1098-6618"],"issn-type":[{"value":"0893-8512","type":"print"},{"value":"1098-6618","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10]]},"assertion":[{"value":"2004-10-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}